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We describe herein the development and experimental validation of a computational
protocol for optimizing a series of 3-hydroxy-pyran-4-one derivatives as HIV integrase
inhibitors (HIV INIs). Starting from a previously developed micromolar inhibitors of
HIV integrase (HIV IN), we performed an in-depth investigation based on an in silico
structure-based combinatorial library designing approach. This method allowed us
to combine a combinatorial library design and side chain hopping with Quantum
Polarized Ligand Docking (QPLD) studies and Molecular Dynamics (MD) simulation.
The combinatorial library design allowed the identification of the best decorations for
our promising scaffold. The resulting compounds were assessed by the mentioned
QPLD methodology using a homology model of full-length binary HIV IN/DNA for
retrieving the best performing compounds acting as HIV INIs. Along with the prediction
of physico-chemical properties, we were able to select a limited number of drug-like
compounds potentially displaying potent HIV IN inhibition. From this final set, based on
the synthetic accessibility, we further shortlisted three representative compounds for the
synthesis. The compounds were experimentally assessed in vitro for evaluating overall
HIV-1 IN inhibition, HIV-1 IN strand transfer activity inhibition, HIV-1 activity inhibition and
cellular toxicity. Gratifyingly, all of them showed relevant inhibitory activity in the in vitro
tests along with no toxicity. Among them HPCAR-28 represents the most promising
compound as potential anti-HIV agent, showing inhibitory activity against HIV IN in the
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low nanomolar range, comparable to that found for Raltegravir, and relevant potency in
inhibiting HIV-1 replication and HIV-1 IN strand transfer activity. In summary, our results
outline HPCAR-28 as a useful optimized hit for the potential treatment of HIV-1 infection
by targeting HIV IN.
Keywords: 3-hydroxy-pyran-4-one, HIV-1 integrase inhibitors (HIV-1 INIs), in silico combinatorial library design,
side chain hopping, hit compounds optimization
INTRODUCTION
HIV-1 integrase (IN) represents an attractive target in anti-HIV
drug design mainly due to its specificity. Accordingly, HIV-1
IN does not have a functional equivalent in humans and plays
a unique role in establishing irreversible and productive viral
infections (Debyser et al., 2002; Delelis et al., 2008). This viral
key enzyme catalyzes the insertion of proviral DNA, derived from
reverse transcription of HIV-1 RNA, into the genome of the
host-infected cells. The insertion is achieved through a two-step
enzymatic process which starts with endonucleolytic cleavage of a
terminal dinucleotide (GT) from each 3′-end of the proviral DNA
(termed “3′-processing”), followed by a second reaction, known
as “strand transfer” (ST), involving a concerted nucleophilic
attack, by the reactive 3′-OH ends of the viral processed DNA to
the host chromosomal DNA. As a result, a the covalent joining
of the two DNA strands is observed (Chiu and Davies, 2004;
Pommier et al., 2005). Both reactions are accomplished by the
catalytic core domain of HIV-1 IN which contains two divalent
metal ion cofactors (Mg2+). These metal ions are coordinated
by three catalytic carboxylate residues: Asp64, Asp116, and Glu152
(DDE triad) within the enzyme active site (Dyda et al., 1994;
Neamati et al., 2002).
Targeting the metal cofactors within the active site of a
viral metal-activated enzyme like HIV-1 IN has emerged as
an attractive and validated strategy for the development of
novel anti-HIV agents (Rogolino et al., 2012). With this aim,
a metal binding pharmacophore model has been exploited
for the design of diverse HIV-1 integrase inhibitors (HIV-
1 INIs) as depicted in Figure 1A. This model is represented
by two distinctive structural features: (1) a planar metal
binding group (MBG), able to interact with the metal centers
within the IN active site, and (2) a pendent aromatic or
hetero-aromatic hydrophobic moiety located in close proximity
of the MBG (Kawasuji et al., 2006a,b; Johns and Svolto,
2008). Continuous efforts in exploiting this pharmacophore
model have culminated in the design and subsequent FDA
approval of three INIs for clinical use as effective anti-HIV
drugs: Raltegravir (RLT), Elvitegravir (EVG), and Dolutegravir
(DTG) in 2007, 2012, and 2013, respectively (Figure 1B;
Rowley, 2008; Sato et al., 2009; Katlama and Murphy, 2012).
A variety of MBGs have been extensively studied to design
innovative and effective INIs (Liao et al., 2010; Di Santo, 2014).
Recently, we were particularly interested in taking advantage of
the 3-hydroxy-4-pyranone (HP) scaffold for the development of
novel HIV-1 INIs due to its application as MBG in the design
of several inhibitors of numerous Zn2+, Mg2+, Mn2+, and Cu2+
dependent proteins. Accordingly, HP derivatives represent an
impressive class of heterocyclic ligands with strong bidentate
chelating capacity toward metal ions (Santos et al., 2012; Rostami
et al., 2015; Sirous et al., 2015). As a first example of the potential
of this structural template in HIV-IN inhibition, a series of HP
compounds featuring a unique C-2 carboxamide moiety, namely
3-hydroxyl-pyran-4-one-2-carboxamide derivatives (HPCARs),
were rationally designed and recently reported by us (Figure 2;
Sirous et al., 2019). The proposed chemotypes were characterized
by a chelating triad motif effectively coordinating the two metals
according to the pharmacophore shared by INIs. Moreover,
an aromatic backbone attached to the amide portion through
a linker (substituted benzyl and phenylethyl moieties) was
considered for providing the essential interactions with the
hydrophobic pocket of the enzyme. Most of these HPCAR
analogs offered favorable inhibitory potencies in both enzymatic
and cell-based antiviral assays with low micromolar IC50 values.
In particular, the substitution at the para position of the
aromatic phenyl ring led to the identification of two halo-
benzyl derivatives HPb and HPd (Figure 2) as promising lead
HIV-1 IN inhibitors with IC50 values of 0.37 and 0.7µM,
respectively (Sirous et al., 2019).
In our quest for the search of innovative and effective
INIs and considering the above-mentioned findings, we decided
to design novel optimized derivatives exploiting the HPCAR
chemotype. In this study, we performed the replacement of the
pendant aromatic portion with other heterocyclic moieties in
order to maintain the strong hydrophobic interactions within
the HIV-1 IN binding site, with the possibility to explore
additional functional groups for maximizing the contacts that
could further stabilize the binding mode of the novel derivatives,
leading to compounds with improved activity against HIV-1
IN. Accordingly, in the present study, an in silico protocol
combining a combinatorial library design procedure coupled
to extensive molecular docking studies and physico-chemical
properties prediction was developed in a step-filtering approach
to identify novel INIs with improved potency with respect
to the HPCAR derivatives. The employed screening workflow
for designing new HIV-1 INIs with suitable potency and
satisfactory physico-chemical properties is illustrated in Figure 3.
Considering the importance of the aromatic portion of INIs
for their binding to both the viral DNA bases, and the
hydrophobic pocket within the catalytic core of IN enzyme
(Kawasuji et al., 2006b), many efforts were made for replacing
the hydrophobic aromatic side chains (substituted benzyl and
phenylethyl moieties) to generate a virtual combinatorial library
of HP-based core derivatives. Accordingly, using side chain
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FIGURE 1 | (A) Graphical depiction of the pharmacophore model for HIV-1 INIs. (B) Chemical structure of the FDA approved HIV-1 INIs. Atoms in blue are part of
MBG of the molecules able to chelate the two metal ions. The hydrophobic aromatic moiety of each compound is highlighted in red.
FIGURE 2 | General structure of 3-hydroxy-4-pyranone (HP) based inhibitors previously designed in our laboratory and two halogenated derivatives identified as lead
compounds. The proposed chemotype satisfies minimal pharmacophore features for HIV-1 IN inhibition: the metal chelating triad (blue) and terminal hydrophobic
benzyl group (red). The most promising HP compounds are shown with the IC50 and EC50 values for IN inhibitory and anti-HIV activities.
hopping strategy, various cyclic and heterocyclic fragments were
attached to the defined position of theHP core in order to find the
ideal sidechains with the highest predicted binding affinity for the
IN active site. Finally, for validating the computational approach
three representative hit candidates identified from this screening
workflow were selected, further studied by molecular dynamics
(MD) simulations in order to gain additional information about
their mechanism of action as INIs, synthesized and submitted to
biological evaluation for their HIV-1 IN inhibitory and anti-HIV-
1 activities.
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FIGURE 3 | Screening workflow employed in the present study for the in silico rational design of new HPCAR derivatives. The core of HPCAR was marked in a blue
box. The hydrophobic fragment, AR group, is depicted as a red circle. During combinatorial library screening, diverse sets of fragments were provided from reagent file
libraries and attached to the main core at the defined attach positions. The attach position in the scaffold structure is indicated as a yellow vector.
MATERIALS AND METHODS
Computational Details
Ligand Preparation
The 3D structure of the two investigated HPCAR
derivatives (substituted with benzyl and phenylethyl moieties)
were built by the 3D-sketcher module in Maestro suite (Maestro,
version 9.2; Schrödinger, LLC, New York, NY, 2011). Molecular
energy minimization of the structures was performed in
MacroModel environment using the OPLS-AA 2005 as force
field (Jorgensen et al., 1996; Kaminski et al., 2001). GB/SA
model was utilized in order to simulate the solvent effects
applying “no cut-off” for non-bonded interactions (Still et al.,
1990). PRCG method with 1,000 maximum iterations and
0.001 gradient convergence threshold was employed. The
same protocol was applied to the novel designed compounds
obtained by the combinatorial screening (144 molecules) before
submitting them to QPLD procedure. Furthermore, all the
compounds were accurately prepared with LigPrep application
implemented in Maestro suite (Gasser et al., 2015). Finally the
most probable ionization state of the compounds was retrieved
by Chemicalize (https://chemicalize.com/) as already reported
by us (Brogi et al., 2018).
Protein Preparation
Computational studies were conducted using our recently
described theoretical model of full-length HIV-1 IN in complex
with viral DNA and Mg2+ cofactors (Sirous et al., 2019).
The model was subjected to Protein Preparation Wizard
protocol implemented in Maestro. This protocol allowed us
to obtain a reasonable starting structure of the protein for
molecular modeling calculations by a series of computational
steps as described (Cappelli et al., 2013; Brogi et al., 2017a,b).
Finally, the refined HIV-1 IN model was used for further
computational studies.
Generation of Combinatorial Hits
“Combinatorial library enumeration” option available in
CombiGlide (CombiGlide, version 2.7; Schrödinger, LLC: New
York, 2011), a combinatorial screening software distributed by
Schrödinger, was used to carry out structure-based combinatorial
library design studies. This software provides the tools for
accelerating the lead optimization process, helping in the
generation of libraries of optimized derivatives to be selected
for the further synthesis. In this direction, two HPCAR
derivatives containing methylene and ethylene linkers between
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the chelating region and the aromatic moiety, identified from
our previous studies (Sirous et al., 2019), were selected as
main cores. For each investigated compound, a side chain
hopping strategy was successfully applied for replacing the
hydrophobic side chain, of the selected main cores, with
different aromatic or heteroaromatic fragments as shown in
Figure 3. This method employs the reagent files, chosen by the
operator, as a source of fragments with various structures. The
following steps are used to generate a new combinatorial library
of ligands.
Reagents Preparation
In this step of CombiGlide workflow, a library of reagents
containing diverse sets of fragments was built. The elements
of this library can be selected from the available databases or
generated by the operator. In fact, in the presented work, in
addition to the reagent libraries provided by Maestro software,
other reagent libraries with different aromatic groups were
downloaded from Zinc fragment database (Irwin and Shoichet,
2005; Irwin et al., 2012) as SDF file format and submitted to
the reagent preparation facility in the CombiGlide environment.
Then the tasks in the reagent preparation process are: (i) the
selection of the source of reagent structures; (ii) the selection of
a reagent type (a functional group), and finally (iii) the structural
conversion from the 2D structure to the 3D one. The selection
of a reagent type was done considering the bond that will be
replaced in accordance to the functional group formed when
the reagent is added to the core. In this context, primary amine
set was selected as reagent type. The detailed description of this
reagent type is provided in Table 1. Concerning this reagent type,
R represents the part of reagent that was kept in the process of
combinatorial library generation. The bond that was broken to
attach the reagent to the core was marked with a line crossing the
bond. After running reagent preparation job, the output structure
file in .bld format, containing properly prepared reagents, was
used in the combinatorial screening process by CombiGlide.
Defining the Core and Attachments
The core is the structural element that is maintained throughout
the combinatorial experiment. The attachment positions for each
core were defined and the previously prepared reagents file was
associated with each attachment point. The attachment point
comprises bonds from the core structure that will be replaced in
the build process. Considered the role of the hydrophobic side
chain of the investigated HPCAR derivatives in binding both
the viral DNA and the hydrophobic pocket within IN active site
(Sirous et al., 2019), the replacement of benzyl and phenethyl
TABLE 1 | Detailed description of predefined functional group type selected in the
reagents preparation step of combinatorial library design.
Structure of
reagent type
Name of reagent
type
Definition of R
Amine_Primary_
General_N_H
R can be alkyl, aryl. R cannot have a
carbonyl carbon attached to the
nitrogen of the amine.
amine moieties with different amine fragments from the reagents
file, with other hydrophobic moieties, was performed.
Setting Up CombiGlide Docking Calculations
The docking step represents the main step of the combinatorial
screening process in which a series of docking calculations are
performed to screen out molecules that do not have satisfactory
docking scores. In fact, on a core with a constant structure,
CombiGlide attaches sidechains at defined positions of the core,
and performs a docking calculation of the resulting compounds
into the active site of HIV-1 IN, to assess the potential affinity
of the new compounds. The grid box for the docking calculation
was centered on the centroid between the two Mg2+ ions which
roughly represents the center of the active site. The cubic grid box
was adjusted based on a size capable of accommodating ligands
with a length 15 Å. As part of grid generation procedure, metal
constraints for the receptor grids were also applied. The other
options and parameters in this step were set as default and then
docking of the librarymembers into the homologymodeled HIV-
1 IN active site was performed using the extra precision method
(XP) in CombiGlide docking. At the end of the process a focused
combinatorial library of more than 37,000 compounds was
obtained for each studied core-containing molecule. The total
structures obtained from combinatorial screening were sorted on
the basis of their GlideScore (Glide, Version 5.7, Schrödinger,
LLC, New York, NY, 2011; Friesner et al., 2004). The compounds
with the better XPGlide scores compared with the corresponding
core-containing molecules were selected for further studies. The
interactions of these compounds, into HIV-1 IN active site, were
assessed by using ligand-interaction diagram implemented in
Maestro suite and visualized by PyMOL (PyMOL Molecular
Graphics System, Version 1.6-alpha, Schrödinger, LLC, New
York, NY, 2013).
Molecular Properties Prediction
The molecules selected from in silico combinatorial screening
were evaluated using a series of filtering criteria for drug-like
properties. In this regard, QikProp application (QikProp, version
3.4, Schrödinger, LLC, New York, NY, 2011) implemented in
the Maestro suite was used for ADME-T properties predictions
(Rostami et al., 2015; Zaccagnini et al., 2017). This step
was performed to select compounds from each library with
appropriate physico-chemical properties using the range values
recommended by QikProp. Especially, Lipinski’s rules of five,
membrane permeability, lipophilicity, cardiotoxicity, or potential
interaction with hERG K+ channel were considered as important
criteria and investigated for filtering (Lipinski et al., 2001).
Default settings were employed for these calculations. The
compounds derived from the above-mentioned calculation were
evaluated for their potential capability to behave as “Pan
Assay Interference Compounds” (PAINS). This calculation was
performed by means of FAFDrugs4.0 (http://fafdrugs4.mti.univ-
paris-diderot.fr/) (Lagorce et al., 2008, 2011; Vallone et al.,
2018; Brindisi et al., 2019). PAINS compounds are chemical
compounds that tend to display activity against a wide range
of targets by nonspecific interactions or by altering the results
of the biological tests. The compounds containing this kind of
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moieties, that are often present in PAINS compounds, could be
false positive hits and in general should be removed from the
designed series (Baell and Holloway, 2010).
Quantum Polarized Ligand Docking (QPLD)
In order to narrow down the number of the potential INIs
and for improving the reliability of the protocol, the quantum
polarized ligand docking (QPLD) calculations were performed
for the resulting compounds with satisfactory physico-chemical
properties. These compounds were docked into the modeled
HIV-1 IN using QPLD protocol implemented in Schrödinger
2011 (Schrödinger Suite 2011: QM-Polarized Ligand Docking
protocol; Glide, Version 5.7, Schrödinger, LLC, New York, NY,
2011; Jaguar, version 7.8, Schrödinger LLC, New York, NY, 2011;
QSite version 5.7, Schrödinger LLC, New York, NY, 2011) (Irwin
et al., 2012). This step was added to improve the accuracy of
classical docking calculation. In fact, this procedure aims to
improve the partial charges on ligand atoms by replacing them
with charges derived from quantum mechanical calculations on
the ligand in the field of the receptor (Paolino et al., 2018).
Within the QPLD framework, the ligand atoms are treated at
the Quantum Mechanical (QM) level, whereas the IN enzyme
including the Mg2+ ions as Molecular Mechanical (MM) region
are described using the OPLS force field parameters. In this
way, the same grid file previously employed in the CombiGlide
step was used. The best docked compounds obtained from
the previous CombiGlide docking calculations followed by the
evaluation of the physico-chemical properties, were selected in
the ligand option. In the first step of the QPLD calculation,
compounds were initially docked into the active site of IN
enzyme. The initial docking calculations were carried out using
Glide standard precision (SP) docking protocol, generating 5
poses per docked molecule. In the second step, the polarizable
ligand charges induced by the protein field were calculated
with QSite software which is coupled with Jaguar quantum
mechanics engine (Jaguar, version 7.8, Schrödinger LLC, New
York, NY, 2011). In this regard, the QM charge calculations of
the best scoring poses for each ligand were carried out using
density functional theory (DFT) method with the B3LYP/6-
31G∗/LACVP∗ basis set within the protein environment defined
by the OPLS-2005 force field. Finally, the ligands with modified
partial charges were redocked into the IN active site using Glide
XP mode of docking considering 10 poses for each ligand. The
potential inhibitors were selected based on the lower values of
XP GlideScore and the key interactions between the ligand and
HIV-1 IN active site.
Ligand Binding Energy Calculations
The best docked pose of ligands selected from previous QPLD
calculations were subjected to a subsequent analysis with MM-
GBSA process implemented in Prime software (Prime, version
3.0, Schrödinger LLC, New York, NY, 2011) (Brindisi et al.,
2015). This method was employed to predict binding affinity
and relative free-binding energy (1Gbind) between ligands and
HIV-1 IN with further accuracy. The MM-GBSA approach
combines MM energies with a continuum solvent generalized
Born (GB) model for polar solvation and with a solvent-
accessible surface area (SASA) for non-polar solvation term.
In this way, the best ligand poses were subjected to energy
minimization by local optimization feature in the Prime. During
this process, the ligand strain energy was also considered. Ligand
binding energies were calculated using the OPLS-2005 force field
and generalized-Born/surface area continuum solvent model as
previously reported by us (Brindisi et al., 2015, 2016; Maquiaveli
et al., 2016; Brogi et al., 2017a; Vallone et al., 2018).
Molecular Dynamics Simulation
MD simulations studies were performed by means of Desmond
4.8 academic version, provided by D. E. Shaw Research
(“DESRES”), using Maestro as graphical interface (Desmond
Molecular Dynamics System, version 4.8, D. E. Shaw Research,
New York, NY, 2016. Maestro-Desmond Interoperability Tools,
version 4.8, Schrödinger, New York, NY, 2016). The calculation
was performed using the Compute Unified Device Architecture
(CUDA) API (Nickolls et al., 2008) employing two NVIDIA
GPU (Brindisi et al., 2019). The calculation was performed
on a system comprising 72 Intel Xeon E5-2695 v4@2.10 GHz
processors and two NVIDIA GeForce 1070 GTX GPU. The
complexesHPCAR-28/IN,HPCAR-89/IN, andHPCAR-142/IN
were prepared by Protein Preparation Wizard protocol. The
complexes were positioned into an orthorhombic box filled
with water (TIP3P model). OPLS_2005 force field was used in
MD calculation. The physiological concentration of monovalent
ions (0.15M) was simulated by adding Na+ and Cl− ions.
Constant temperature (300K) and pressure (1.01325 bar) were
employed with NPT (constant number of particles, pressure, and
temperature) as ensemble class. RESPA integrator (Humphreys
et al., 1994) was used in order to integrate the equations of
motion, with an inner time step of 2.0 fs for bonded interactions
and nonbonded interactions within the short-range cut-off.
Nose-Hoover thermostats (Hoover, 1985) were used to maintain
the constant simulation temperature, and the Martyna-Tobias-
Klein method (Martyna et al., 1994) was used to control the
pressure. Long-range electrostatic interactions were evaluated
adopting particle-mesh Ewaldmethod (PME). The cut-off for van
der Waals and short-range electrostatic interactions was set at
9.0 Å. The equilibration of the systems was performed with the
default protocol provided in Desmond, which consists of a series
of restrained minimizations and MD simulations used to slowly
relax the system. By following this protocol, a single trajectory of
100 ns was obtained. We performed five independent MD runs
for each mentioned complex with an aggregate simulation time
of 0.5µs to provide more reliable results. The trajectory files were
investigated by simulation interaction diagram tools, simulation
quality analysis and simulation event. The described applications
were used to generate all plots regardingMD simulations analysis
included in the manuscript as reported in the Results and
Discussion section.
Chemistry
All reactants and reagents were purchased from Alfa Aesar and
Sigma–Aldrich as “synthesis grade.” Chemical reactions were
monitored by analytical thin-layer chromatography (TLC) using
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several solvent systems with different polarity onMerck Silica Gel
60 F254 (0.040–0.063mm) with detection by UV.Merck Silica Gel
60 (0.040–0.063mm) was used for column chromatography. 1H
NMR and 13C NMR spectra were recorded on a Varian 300 MHz
(USA) spectrometer using the residual signal of the deuterated
solvent as internal standard. Splitting patterns of signals are
indicated as singlet (s), doublet (d), triplet (t), multiplet (m),
broad (br), and doublet of doublet (dd). The values of chemical
shifts (δ) are reported in ppm and coupling constants (J) in
hertz (Hz). Electrospray ionization-mass spectrometric (ESI-MS)
were acquired with an Agilent 1100 series LC/MSD spectrometer
equipped with a multimode ion source and by using methanol
as solvent.
3-(Benzyloxy)-6-Methyl-4-oxo-4H-Pyran-2-
Carboxylic Acid, BPCA
This key carboxylic acid intermediate was prepared according to
a previously reported procedure (Sirous et al., 2019).
Procedures for the Synthesis of Amine Fragments
AM (1–3)
With the aim of synthesizing the representative hit candidates,
three kinds of different amine fragments were applied for
amide coupling with the carboxylic acid functional group of
intermediate BPCA. The required amine compounds were
synthesized using the following methods.
Procedure for the Preparation of
(3-Fluoro-5-(pyridin-2-yl)phenyl)methanamine (AM-1)
3-Fluoro-5-(pyridin-2-yl)benzonitrile (3)
Starting from 2-bromopyridine 1, a Suzuki coupling with (3-
cyano-5-fluorophenyl)boronic acid 2 catalyzed by tetrakis (tri-
phenylphosphine) palladium (0) provided the phenyl-pyridine
derivative 3. In this reaction tetrakis was generated in situ
from palladium (II) acetate and triphenylphosphine (Tan et al.,
2014). To a vigorously stirred yellowish solution of palladium
(II) acetate (0.28 g, 1.26 mmol, 0.2 eq) and triphenylphosphine
(1.66 g, 6.33 mmol, 1 eq) in 4mL dioxane/water (3:1), a premixed
solution of 2-bromopyridine 1 (1.00 g, 6.33 mmol, 1 eq) in
dioxane (50mL), and a solution of potassium carbonate (2.62 g,
19 mmol, 3 eq) in water (28mL) was added. The reaction
mixture was allowed to stir for 15min under N2. This step was
followed by the drop-wise addition of a solution of (3-cyano-5-
fluorophenyl)boronic acid 2 (1.15 g, 6.96 mmol, 1.1 eq) in 8mL
dioxane/water (4:1) via a syringe. After the final addition, the
reaction mixture was refluxed at 100◦C in an oil bath under
N2. The progression of the reaction was monitored by TLC. The
reactionwas completed after 24 h. After that, the reactionmixture
was cooled down to the room temperature and subsequently
filtered through a short Celite pad. The filter cake was washed
with dichloromethane (25mL). The filtrate solution was diluted
with water and extracted with dichloromethane (3 × 100mL).
The organic layers were combined, dried over sodium sulfate,
filtered and then evaporated in vacuo to yield a crude product.
The crude product was purified by flash chromatography on silica
gel, eluting with 9:1 petroleum ether: ethyl acetate, to give 3 as a
white solid (Tan et al., 2014). Yield: 64%, 1H NMR (300 MHz,
CDCl3) δ (ppm): 8.75 (1H, d, J = 6.25Hz, C6′-H), 8.42 (1H, d, J
= 6.00Hz, C4-H), 7.80 (2H, s, C6-H, and C2-H), 7.62–7.72 (1H,
m, C4′-H), 7.22–7.40 (2H, m, C3′-H and C5′-H).
(3-Fluoro-5-(pyridin-2-yl)phenyl)methanamine (AM-1)
Dry NiCl2 was prepared from hydrated NiCl2. In this way,
NiCl2•6H2O was used after drying in an oven at 250◦C until
its color turned from green to golden yellow. Then, it was
powdered and stored in a vacuum desiccator for reaction. In
a typical procedure (Caddick et al., 2003), nitrile compound
3 (0.2 g, 1.00 mmol, 1 eq) and anhydrous nickel (II) chloride
(0.13 g, 1 mmol, 1 eq) were dissolved in dry ethanol (8mL).
Then, sodium borohydride (0.11 g, 3 mmol, 3 eq) was cautiously
added in three portions to the vigorously stirred reaction mixture
at room temperature. A black precipitate appeared during the
addition of NaBH4. When the addition of NaBH4 was completed,
stirring was continued and the progress of the reaction was
monitored by TLC. After the complete disappearance of the
nitrile compound in almost 15min, the reaction mixture was
filtered through a Celite pad. The filtered nickel boride precipitate
was washed with ethanol (10mL). The filtrate was collected,
diluted with water (30mL), and extracted with ethyl acetate
(3 × 30mL). The organic phase was combined, dried over
sodium sulfate, filtered and concentrated on a rotary vacuum
evaporator to afford a crude product. The crude product
was purified by flash chromatography on silica gel, eluting
with 4:1 chloroform:methanol to give the corresponding amine
compound AM-1 as a white solid (Caddick et al., 2003). Yield:
65%, 1HNMR (300MHz, DMSO-d6) δ (ppm): 8.66 (2H, s, NH2),
8.12 (1H, d, J = 6Hz, C6′-H), 7.69–7.98 (3H, m, Ar), 7.59–7.70
(1H, br, C4′-H), 7.20–7.40 (2H, m, C3′-H and C5′-H), 4.76 (2H,
s, CH2NH2).
Procedure for the Preparation of
(3-(2-methyl-1H-imidazol-4-yl)phenyl)methanamine
(AM-2)
4,5-Dibromo-2-methyl-1H-imidazole (5)
2-Methyl-1H-imidazole 4 (10 g, 0.122mol) was dissolved in
300mL chloroform and cooled to the temperature between 0
and −5◦C using salty ice bath. 48.66 g (15.60mL, 0.305mol)
bromine was added to the reaction mixture drop-wise via a
dropping funnel over 20min. The reaction mixture was allowed
to stir at room temperature. The progression of the reaction
was monitored by TLC. The reaction was completed after
20 h. During this time, the reaction product precipitated as an
orange solid. In the next step, the reaction mixture was cooled
to 0◦C in a salty ice bath and 250mL of NaOH (2N) was
added drop-wise to the reaction mixture in order to quench
unreacted bromine. The orange precipitate was filtered off and
washed with water, dried in vacuo at 40◦C for 12 h to give the
yellow solid of 5 (Alonso-Alija et al., 2003). Yield: 43%, 1H
NMR (300 MHz, DMSO-d6) δ (ppm): 8.68 (1H, brs, NH), 2.39
(3H, s, CH3).
4-Bromo-2-methyl-1H-imidazole (6)
4,5-Dibromo-2-methyl-1H-imidazole 5 (5.0 g, 20.84 mmol) was
suspended with sodium sulfite (80 g, 635 mmol) in 200mL water
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and 100mL ethanol. The suspension was refluxed at 100◦C in
an oil bath. The progression of the reaction was monitored by
TLC. The reaction was completed after 48 h and the reaction
mixture was extracted with ethyl acetate (3 × 100mL). The
organic phases were collected, dried over sodium sulfate, filtered
and then evaporated in vacuo to yield a white solid as pure
product 6 (Alonso-Alija et al., 2003). Yield: 75%, 1H NMR (300
MHz, DMSO-d6) δ (ppm): 12.00 (1H, brs, NH), 7.05 (1H, d, J =
1.80Hz, C5-H), 2.21 (3H, s, CH3).
3-(2-Methyl-1H-imidazol-4-yl)benzonitrile (8)
Nitrile compound 8 was synthesized according to same Suzuki
procedure described for the preparation of compound 3 (Tan
et al., 2014). Briefly, starting from a solution of palladium
(II) acetate (0.42 g, 1.86 mmol, 0.2 eq) and triphenylphosphine
(2.44 g, 9.32 mmol, 1 eq) in 6mL dioxane/water (5:1), a
solution of bromo-imidazole derivative 6 (1.5 g, 9.32 mmol,
1 eq) in dioxane (70mL), a solution of potassium carbonate
(3.87 g, 28 mmol, 3 eq) in water (40mL) and a solution of (3-
cyanophenyl) boronic acid 7 (1.51 g, 10.252 mmol, 1.1 eq) in
10mL dioxane/water (5:1) were used in Sequence. Crude product
was purified by flash chromatography on silica gel using 3:1
petroleum ether: ethyl acetate as the eluent to yield 8 as a white
solid (Tan et al., 2014). Yield: 70%, 1H NMR (300 MHz, DMSO-
d6) δ (ppm): 11.95 (1H, brs, NH), 8.10 (1H, s, C2′-H), 8.00 (1H,
d, J = 9.40Hz, C6′-H), 7.45–7.68 (3H, m, C5-H, C4′-H, C5′-H),
2.20 (3H, s, CH3). ESI-MS (+) m/z (%): 183.9 [M+H]+ (100).
(3-(2-Methyl-1H-imidazol-4-yl)phenyl)methanamine
(AM-2)
Amine compound AM-2 was synthesized according to the
same procedure described for reduction of nitrile 3 to the
corresponding primary amine AM-1 (Caddick et al., 2003). In
this way, starting from nitrile compound 8 (0.5 g, 2.73 mmol,
1 eq), 0.353 gr (2.73 mmol, 1 eq) of anhydrous nickel (II)
chloride, and 0.31 g (8.19 mmol, 3 eq) sodium borohydride were
used. The purification was performed via silica flash column
chromatography using 4:1 chloroform: methanol as the eluent
to yield the corresponding amine product AM-2 as a white
solid (Caddick et al., 2003). Yield: 61%, 1H NMR (300 MHz,
DMSO-d6) δ (ppm): 11.72 (1H, brs, NH), 7.70–8.50 (5H, m, C5-
H, C2′-H, C4′-H, C5′-H and C6′-H), 3.70 (2H, s, CH2NH2),
2.25 (3H, s, CH3).
Procedure for the Preparation of
(3-(1H-pyrrol-1-yl)phenyl)methanamine (AM-3)
3-(1H-Pyrrol-1-yl)benzonitrile (11)
Phenylpyrrole 11 was synthesized through a Clauson–Kaas
reaction with 3-aminobenzonitrile 9 (Chatzopoulou et al., 2013).
To a solution of 3-aminobenzonitrile 9 (1.00 g, 8.46 mmol, 1
eq) in 15.0mL of 1,4-dioxane, 2,5-dimethoxytetrahydrofuran 10
(1.23 g, 9.306 mmol, 1.1 eq) dissolved in 7.0mL of 1,4-dioxane
were added. The reaction mixture was refluxed for 5min, and
then 3mL of hydrochloric acid 5N was added drop-wise. The
reaction mixture was refluxed for 25min until the reaction was
completed. After cooling to room temperature, water was added
to the reaction mixture. The reaction mixture was extracted with
dichloromethane (3 × 50mL). The organic layer was dried over
anhydrous sodium sulfate, filtered, and concentrated in vacuo.
Flash chromatography on silica gel, eluting with 4:1 petroleum
ether: ethyl acetate, afforded compound 11 as an amorphous
white solid (Chatzopoulou et al., 2013). Yield: 82%, 1HNMR (300
MHz, CDCl3) δ (ppm): 7.48–7.52 (4H, m, Ar), 7.08 (2H, t, J =
3.00Hz, C2′-H, C5′-H), 6.79 (2H, t, J = 3.00Hz, C3′-H, C4′-H).
(3-(1H-Pyrrol-1-yl)phenyl)methanamine (AM-3)
Amine compound AM-3 was synthesized according to the
same procedure described for the reduction of nitrile 3 to the
corresponding primary amine AM-1 (Caddick et al., 2003). In
this way, starting from nitrile 11 (0.5 g, 2.97 mmol, 1 eq),
0.385 g (2.97 mmol, 1 eq) of anhydrous nickel (II) chloride, and
0.337 g (8.91 mmol, 3 eq) sodium borohydride were used. The
purification was performed via silica column chromatography
using 4:1 chloroform: methanol as the eluent to yield the
corresponding amine AM-3 as a white solid (Caddick et al.,
2003). Yield: 75%, 1H NMR (300 MHz, DMSO-d6) δ (ppm): 7.52
(1H, s, C2-H), 7.27–7.42 (4H, m, 3H: C3-H, C4-H and C5-H;
1H: C2′-H), 7.18 (1H, d, J = 4.40Hz, C5′-H), 6.24 (2H, s, C3′-H,
C4′-H), 3.77 (2H, s, CH2NH2).
General Procedure for the Synthesis of
3-(benzyloxy)-6-methyl-N-(Substituted
benzyl)-4-oxo-4H-pyran-2-carboxamide Derivatives,
BPCAR
To a vigorously stirred suspension of intermediate BPCA
(100mg, 0.38 mmol, 1 eq) in dry dichloromethane (8mL),
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDCI) (72.5mg, 0.38 mmol, 1 eq) was added and the mixture
was stirred for 30min under N2 to provide a clear yellow solution.
Then, N-hydroxysuccinimide (NHS) (43.7mg, 0.38 mmol, 1 eq)
was added to the stirring solution and the mixture was allowed
to stir for 3 h under N2 to produce the activated ester 12 as
reported in the Chemistry details in the Result and Discussion
section. After this step and complete consumption of the starting
material BPCA, desired prepared amine fragment (1.5 eq) was
added to the reaction mixture. The reaction was stirred at
room temperature for 3 days under N2. During this time, the
progression of the reaction was monitored by TLC. Then, the
reaction mixture was poured into a separatory funnel and the
dichloromethane layer was washed with water (2 × 20mL).
The organic phase was collected, dried over anhydrous sodium
sulfate, filtered, and concentrated in vacuo to yield a crude
solid. The obtained solid was purified via silica flash column
chromatography to give the desired carboxamide product as a
pure substance (Sheehan et al., 1965; Sirous et al., 2019).
3-(Benzyloxy)-N-(3-fluoro-5-(pyridin-2-yl)benzyl)-6-
methyl-4-oxo-4H-pyran-2-carboxamide
(BPCAR-28)
Carboxamide derivative BPCAR-28 was prepared according to
the general procedure, using amine compound AM-1 (115mg,
0.57 mmol, 1.5 eq). The purification of the crude product using
silica flash column chromatography, eluting with 1:1 petroleum
ether: ethyl acetate solution, afforded the carboxamide product
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BPCAR-28 as a white solid. Yield: 44%, 1H NMR (300 MHz,
CDCl3) δ (ppm): 8.74 (1H, d, J = 5.5Hz, C6′-H), 8.18(1H, brs,
NHCH2), 7.88 (1H, d, J = 5.5Hz, Ar: C4-H), 7.76 (2H, s, Ar: C2-
H and C6-H), 7.18–7.40 (6H, m, 5H: OCH2C6H5; 1H: C4′-H),
7.02–7.16 (2H, m, C3′-H and C5′-H), 6.24 (1H, s, C5-H), 5.36
(2H, s, OCH2-C6H5), 4.44 (2H, d, J = 8.00Hz, NHCH2-C6H4),
2.38 (3H, s, 6-CH3).
3-(Benzyloxy)-6-methyl-N-(3-(2-methyl-1H-imidazol-
4-yl)benzyl)-4-oxo-4H-pyran-2-carboxamide
(BPCAR-89)
Carboxamide derivative BPCAR-89 was prepared according to
the general procedure, using amine compound AM-2 (0.107 g,
0.57 mmol, 1.5 eq). The purification of the crude product using
silica flash column chromatography, eluting with 1:1 petroleum
ether: ethyl acetate solution, afforded the carboxamide product
BPCAR-89 as a white solid. Yield: 38%, 1H NMR (300 MHz,
Acetone-d6) δ (ppm): 8.41 (1H, brs, NHCH2), 7.82 (1H, s,
C2′-H), 7.70 (1H, d, J = 12.00Hz, C4′-H),7.23–7.40 (7H, m,
5H:OCH2-C6H5; 2H: C5′-H and C6′-H), 7.18 (1H, d, J =
12.00Hz, C5
′′
-H), 6.28 (1H, s, C5-H), 5.30 (2H, s, OCH2-C6H5),
4.50 (2H, d, J = 6.00Hz, NHCH2-C6H4), 2.40 (3H, s, CH3), 2.24
(3H, s, CH3).
N-(3-(1H-Pyrrol-1-yl)benzyl)-3-(benzyloxy)-6-methyl-
4-oxo-4H-pyran-2-carboxamide
(BPCAR-142)
Carboxamide derivative BPCAR-142 was prepared according to
the general procedure, using amine compound AM-3 (98.2mg,
0.57 mmol, 1.5 eq). The purification of the crude product using
silica flash column chromatography, eluting with 1:1 petroleum
ether: ethyl acetate solution, afforded the carboxamide product
BPCAR-142 as a white solid. Yield: 48%, 1H NMR (300 MHz,
CDCl3) δ (ppm): 8.12 (1H, t, J = 8.00Hz, NHCH2), 7.16–
7.38 (8H, m, 5H: OCH2C6H5; 3H: C2′-H, C4′-H and C5′-H),
7.01–7.08 (3H, m, 2H: C2
′′
-H, C5
′′
-H; 1H: C6′-H), 6.36 (2H,
t, J = 3.00Hz, C3
′′
-H, C4
′′
-H), 6.25 (1H, S, C5-H), 5.32 (2H,
s, OCH2C6H5), 4.46 (2H, d, J = 8.30Hz, NHCH2C6H4), 2.35
(3H, s, 6-CH3).
General Procedure for the Synthesis of
3-hydroxy-6-methyl-N-(substituted
benzyl)-4-oxo-4H-pyran-2-carboxamide derivatives,
HPCAR
40mg of each of the desired BPCAR derivatives was dissolved
in dry dichloromethane (3mL) and flushed with nitrogen. Then,
the reaction mixture was cooled to the temperature between
0 and −5◦C in salty ice bath and the 1M solution of boron
tribromide in dichloromethane (3 eq) was slowly added drop-
wise via a syringe. The reaction mixture was allowed to stir at
room temperature and the reaction progress was monitored by
TLC. The reaction was completed after almost 3 h. The excess
BBr3 was eliminated at the end of the reaction by the addition
of cold methanol (5mL) to the reaction mixture at 0◦C and
left to stir for half an hour. The mixture was concentrated to
dryness in vacuum and the residue was dissolved several times
in methanol and evaporated. This residue was purified by flash
column chromatography to afford the final pure product (Ma and
Hider, 2015; Sirous et al., 2019).
N-(3-Fluoro-5-(pyridin-2-yl)benzyl)-3-hydroxy-6-
methyl-4-oxo-4H-pyran-2-carboxamide
(HPCAR-28)
Compound HPCAR-28 was prepared according to the general
debenzylation procedure, starting from compound BPCAR-28
(40mg, 0.09 mmol, 1 eq) and 1M solution of boron tribromide in
CH2Cl2 (46µL, 0.27mmol, 3 eq). Purification using flash column
chromatography (eluent: dichloromethane: methanol; 80:20 v/v)
afforded a white solid as final product HPCAR-28. Yield: 71%,
1HNMR (300 MHz, DMSO-d6) δ (ppm): 8.60 (1H, d, J = 5.5Hz,
C6′-H), 8.12 (1H, brs, NHCH2), 7.74 (1H, d, J = 5.5Hz, Ar:
C4-H), 7.62 (2H, s, Ar: C2-H and C6-H), 7.12–7.34 (1H, br,
C4′-H), 7.00–7.13 (2H, m, C3′-H and C5′-H), 6.22 (1H, s, C5-
H), 4.34 (2H, d, J = 8.00Hz, NHCH2-C6H4), 2.34 (3H, s, 6-
CH3). 13C NMR (DMSO-d6) δ (ppm): 173.55 (4-C=O), 164.84
(CONH), 162.72 (C-3), 162.48 (Ar: C3′-F, d, 1JC−F: 220.4Hz),
152.15 (Ar), 147.39 (Ar), 144.05 (C-2), 143.86 (Ar), 136.14 (C-6),
132.32 (Ar), 132.12 (Ar), 124.00 (Ar), 123.09 (Ar), 122.28 (Ar),
116.60 (Ar), 114.11 (Ar), 108.63 (C-5), 42.04 (NHCH2), 19.31
(6-CH3). ESI-MS (+) m/z (%): 355.3 [M+H]+ (100).
3-Hydroxy-6-methyl-N-(3-(2-methyl-1H-imidazol-4-
yl)benzyl)-4-oxo-4H-pyran-2 carboxamide
(HPCAR-89)
Compound HPCAR-89 was prepared according to the general
procedure described above, starting from compound BPCAR-89
(40mg, 0.09 mmol, 1 eq) and 1M solution of boron tribromide in
CH2Cl2 (46µL, 0.27mmol, 3 eq). Purification using flash column
chromatography (eluent: dichloromethane: methanol; 80:20 v/v)
afforded a white solid as final product HPCAR-89. Yield: 82%,
1H NMR (300 MHz, DMSO-d6) δ (ppm): 11.80 (1H, brs, NH
of imidazole ring), 10.63 (1H, brs, NHCH2),7.60 (1H, s, C2′-
H), 7.58 (1H, d, J = 12.00Hz, C4′-H), 7.38 (1H, s, C5"-H),
7.20 (1H, t, J = 12.00Hz, C5′-H), 7.05 (1H, d, J = 12.00Hz,
C6′-H), 6.20 (1H, s, C5-H), 4.40 (2H, d, J = 6.00Hz, NHCH2-
C6H4), 2.24 (6H, s, CH3-a and CH3-b). 13C NMR (DMSO-d6)
δ (ppm): 173.53 (4-C=O), 164.78 (CONH), 162.72 (C-3), 156.60
(C3H4N2: C2), 151.02 (C3H4N2: C5), 147.44 (C-2), 142.54 (Ar),
136.14 (C-6), 134.64 (Ar), 129.47 (Ar), 128.30 (Ar), 125.52 (Ar),
123.14 (C3H4N2: C4), 117.21 (Ar), 112.65 (C-5), 41.53 (NHCH2),
19.30 (6-CH3), 16.60 (CH3-C3H4N2). ESI-MS (+) m/z (%): 340.1
[M+H]+ (100).
N-(3-(1H-Pyrrol-1-yl)benzyl)-3-hydroxy-6-methyl-4-
oxo-4H-pyran-2-carboxamide
(HPCAR-142)
Compound HPCAR-142 was prepared according to the general
procedure, starting from compound BPCAR-142 (40mg, 0.096
mmol, 1 eq) and 1M solution of boron tribromide in CH2Cl2
(49 µL, 0.288 mmol, 3 eq). Purification using flash column
chromatography (eluent: dichloromethane: methanol; 80:20 v/v)
afforded a white solid as final product HPCAR-142. Yield:
86%, 1H NMR (300 MHz, DMSO-d6) δ (ppm): 10.30 (1H, brs,
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NHCH2), 7.2–7.56 (4H, m, C2′-H, C4′-H, C5′-H, C6′-H), 7.0–
7.20 (2H, m, C2′′-H, C5′′-H), 6.23 (2H, d, J = 7.50Hz, C3′′-H,
C4′′-H), 6.18 (1H, s, C5-H), 4.50 (2H, d, J = 7.00Hz, NHCH2),
2.30 (3H, s, 6-CH3). 13C NMR (DMSO-d6) δ (ppm): 173.55
(4-C=O), 164.79 (CONH), 162.72 (C-3), 147.51 (C-2), 142.52
(Ar), 136.19 (C-6), 135.31 (Ar), 128.90 (Ar), 124.37 (Ar), 120.05
(C4H4N: C2, C5), 119.30 (Ar), 117.43 (Ar), 112.67 (C-5), 108.77
(C4H4N: C3, C4), 41.96 (NHCH2), 20.65 (6-CH3). ESI-MS (+)
m/z (%): 324.9 [M+H]+ (30), 346.7 [M+Na]+ (100).
Biological Evaluation
Integrase Assays
The enzymatic integration reactions were carried out as
previously described with minor modifications (Debyser et al.,
2001; Christ et al., 2011). To determine the susceptibility of the
HIV-1 IN enzyme to different compounds, an enzyme-linked
immunosorbent assay (ELISA) adapted from Hwang et al. was
used (Hwang et al., 2000). The overall integration assay uses
an oligonucleotide substrate for which one oligonucleotide (5′-
ACTGCTAGAGATTTTCCACACTGACTAAAAGGGTC-3′) is
labeled with biotin at the 3′ end and the other oligonucleotide
(5′-GACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGT-
3′) is labeled with digoxigenin at the 5′ end. For the strand
transfer assay, a pre-cleaved oligonucleotide substrate (the
second oligonucleotide lacks GT [underlined] at the 3′ end)
was used. The IN enzyme was diluted in 750mM NaCl, 10mM
Tris (pH: 7.6), 10% glycerol, and 1mM β-mercaptoethanol. To
perform the reaction, 4 µL of diluted IN (corresponding to a
concentration of 1.6µM) and 4 µL of annealed oligonucleotides
(7 nM) were added in a final reaction volume of 40µL containing
10mM MgCl2, 5mM dithiothreitol, 20mM HEPES (pH 7.5),
5% polyethylene glycol, and 15% dimethyl sulfoxide. As such,
the final concentration of IN in this assay was 160 nM. The
reaction was carried out for 1 h at 37◦C. Reaction products were
denatured with 30mM NaOH and detected by ELISA on avidin-
coated plates. For determining the effect of compounds on the
3′-processing activity a classical cleavage assay with detection
of products by denaturing gel electrophoresis was performed as
described previously (Debyser et al., 2001; Christ et al., 2011).
Briefly, 0.2 pmol of the radioactive labeled oligonucleotide
substrate (INT1, 32P-5′ TGTGGAAAATCTCTAGCAGT3′;
INT2, 5′ACTGCTAGAGATTTTCCACA 3′) and 10 nmol IN
in a final volume of 10 µL was incubated for 1 h at 37◦C.
The final reaction mixture contained 20mM HEPES (pH
7.5), 5mM dithiothreitol (DTT), 10mM MgCl2, 0.5% (v/v)
polyethylene glycol 8000, 15% DMSO. IN was diluted previously
in 750mM NaCl, 10mM Tris (pH 7.6), 10% glycerol and
1mM β-mercaptoethanol. The reactions were stopped by the
addition of formamide loading buffer (95% formamide, 0.1%
xylene cyanol, 0.1% xylene cyanol, 0.1% bromophenol blue,
and 0.1% sodium dodecyl sulfate). Samples were loaded on
a 15% denaturing polyacrylamide/ureum gel. The extent of
3′-processing or DNA strand transfer was based on measuring
the respective amounts of −2 bands or strand transfer products
relative to the intensity of the total radioactivity present in
the lane. These data were determined using the OptiQuant
Acquisition and Analysis software (Perkin Elmer Corporate,
Fremont, CA).
In vitro Anti-HIV and Drug Susceptibility Assays
The inhibitory effect of antiviral drugs on the HIV-induced
cytopathic effect (CPE) in human lymphocyte MT-4 cell culture
was determined by the MT-4/MTT-assay (Pauwels et al., 1988).
This assay is based on the reduction of the yellow colored 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
by mitochondrial dehydrogenase of metabolically active cells
to a blue formazan derivative, which can be measured
spectrophotometrically. The 50% cell culture infective dose of
the HIV strains was determined by titration of the virus stock
using MT-4 cells. For the drug susceptibility assays, MT-4 cells
were infected with 100–300 50% cell culture infective doses of
the HIV strains in the presence of 5-fold serial dilutions of the
antiviral drugs. The concentration of the compound achieving
50% protection against the CPE of HIV, which is defined as the
50% effective concentration (EC50), was determined. In parallel,
the concentration of the compound destroying 50% of the MT-4
cells, which is defined as the 50% cytotoxic concentration (CC50),
was determined as well.
RESULTS AND DISCUSSION
The main purpose of the present study is to identify novel
chemical entities derived from HPCARs scaffold as new
and useful hit compounds as HIV-1 INIs. Accordingly, an
integrated computational protocol based on combinatorial
library design protocol, physico-chemical properties prediction,
molecular docking calculations, and MD simulation was
developed in a stepwise filtering approach (Figure 3). The
identified hit compounds were synthesized and submitted to
biological evaluation in order to validate the proposed in
silico strategy.
Generation of Combinatorial Hits Using
CombiGlide
As the first step of the developed in silico protocol, HPCAR
derivatives with n = 1 or 2 (Figures 2, 3) were submitted to
CombiGlide software as a combinatorial docking tool. In each
case, combinatorial virtual screening was applied in order to
replace the aromatic groups of the original core, applying side-
chain hopping method. The prepared sets of amine fragments,
available in the library of reagents, were used to replace the
original substituents at each defined attachment point (Figure 3).
Variation in aromatic group resulted in the generation of a
combinatorial library of more than 37,000 hit compounds for
each studied core-containing molecule. The compounds from
each new combinatorial library were sorted by GlideScore values.
Only derivatives with score values lower than −6.0 kcal/mol
were considered. The selected molecules were further analyzed
by visual inspection to find compounds with an appropriate
binding mode according to the key interactions found for HIV-1
INIs. From this first filter, 1,803 combinatorial compounds were
chosen for the next step.
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Molecular Properties Prediction
One of the major goals in drug discovery is the identification
of innovative small molecular scaffolds exhibiting high
efficacy and selectivity against the desired target along with
a satisfactory ADME-T profile. Thus, the second filter in the
screening workflow consisted in the prediction of the ADME-T
properties and drug-like behavior of the above-mentioned 1,803
compounds using QikProp software. This step was performed
to select molecules possessing satisfactory predicted membrane
permeability (QPPCaco-2 and QPPMDCK models > 100),
appropriate lipophilicity (QPlogP) including capability to
cross the blood brain barrier and drug-likeness properties in
accordance with Lipinski’s rule of five. The potential interaction
with hERG K+ channel (QPlog-HERG) was another key
parameter considered in this step of filtering. 146 out of 1,803
compounds were predicted to have pharmacokinetic properties
in the appropriate range. Moreover, the resulting compounds
were filtered for behaving as PAINS using FAF-Drugs4 tool.
Among 146 compounds, only two molecules contain sub-
structural features that marked them as “frequent hitters” in high
throughput screens. Finally, 144 candidates passed this step of
screening and were chosen for the next step. A list of these top
candidates with improved ADMET properties was provided in
the Table S1.
Quantum Polarized Ligand Docking
Simulation
The resulting 144 potential hit molecules were further
computationally analyzed using QPLD calculations for
guaranteeing a better prediction of their binding mode into
HIV-1 IN active site. This docking protocol could provide a
more accurate treatment of electronic interactions especially
within metalloproteins active site, leading to the improvement of
the accuracy of the docking results (Cho et al., 2005; Illingworth
et al., 2008; Paolino et al., 2018). In this step, the potential
inhibitors were selected based on their lower XP GlideScore
and on the ability to engage in critical interactions in the HIV-1
IN active site. At the end, a total of 76 hit candidates with the
favorable XP GlideScore values were identified (Table S2). As
reported in Table S2, the 76 selected hit molecules showed XP
GlideScore values < −6 kcal/mol (the values of the cut-off filters
for the in silico studies were chosen taking into consideration
the values found for the reference compounds RLT, EVG, and
DTG). The detailed analysis of QPLD results indicated that
these compounds adopt a reasonable interfacial binding mode
similar to that found for the approved HIV-1 INIs, namely RLT,
EVG, and DTG (Rostami et al., 2015; Sirous et al., 2015, 2019).
Consistent with docking models of HP derivatives previously
reported (Sirous et al., 2019), the same interaction pattern was
found for the best docked pose of all the selected hit molecules
within HIV-1 IN active site. In this context, combinatorial hits
perfectly occupied the DNA/IN interface with donor oxygen
triad of MBG interacting with both Mg2+ ions through a
bis-bidentate mode of chelation. This orientation enables the
aromatic side chain of the molecule to sit in a hydrophobic
pocket close to the active site generated by the displacement
of the terminal adenosine on the 3′-end of the viral DNA. As
a result, the terminal aromatic moiety of ligands participates
in pi-pi stacking interactions with the viral DNA nucleosides,
DC16 and DG4, and favorable hydrophobic contacts with the
amino acids residues of the catalytic loop, Pro145, Gln146, and
Gly149. Particularly, Pro145 and Gln146 are directly involved in
separation of the viral DNA strands upon the ST reaction. This
can reduce the catalytic loopmobility and thus physically hamper
the binding of the host DNA (Dirac and Kjems, 2001; Dolan
et al., 2009). In some cases, further stabilization of the ligand in
the active site was mediated by H-bonds with Asn117, Pro145,
Gln146, and Glu152 as well as nucleoside residues DG4, DC16, and
DA17. For example, HPCAR-40 was involved in hydrogen bond
interactions with Asn117 and Glu152 and HPCAR-144 formed
hydrogen bonds with Gln146 and Glu152. Furthermore, in most
of the docking models, the position of 4-pyran core of ligands
was suitably located to establish strong hydrophobic interactions
such as a pi-pi stacking with 3′-deoxyadenosine A17 (Table S2).
Prioritization of Hit Compounds Based on
Relative Ligand Binding Energy
Although it is well established that docking calculations are
highly successful in offering reliable ligand poses within the
protein binding site, they often fail to rank compounds with
respect to their binding affinities. This poor correlation may be
due to severe approximations and simplifications employed by
scoring functions of various docking tools. The scoring functions
like GlideScore do not consider some essential thermodynamics
factors in the ligand binding energy calculations such as protein
and ligand solvation energy terms (Pearlman and Charifson,
2001; Taylor et al., 2002). Thus in the subsequent step of
our computational workflow, relative ligand binding energy
calculations using MM-GBSA rescoring method were carried
out on the best docked pose of the ligands obtained from the
previously described docking simulation. This approach may
offer more reliable measuring criteria to prioritize screened HIV-
1 INIs hits for chemical synthesis and biological evaluations as
HIV-1 INIs (Huang et al., 2006). Rescoring using MM-GBSA
leads to minor changes of the ligand conformations within
receptor site. These changes result from minimization of the
ligand in receptor’s environment and consequent stabilization
of receptor-ligand complex. The estimated binding energy
values < −25 kcal/mol were considered to retrieve final set
of combinatorial hits. Final ranking of the ligands in this
step of screening workflow resulted in the identification of 40
top hit compounds as novel HIV-1 INIs, possessing relevant
binding affinities for HIV-1 IN active site. The structures of
these compounds are shown in Table 2. The calculated 1Gbind
of the final selected hits along with their contributions to
total binding energy from various energy components are
provided in Table S3.
Since the screened hit molecules share the same MBG, the
main differences in ligand binding energies values between
these inhibitors could be directly attributed to the hydrophobic
aromatic moieties characterized by significant chemical diversity,
including bicyclic and tricyclic structures. Inspection of energy
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TABLE 2 | Chemical structures of 40 top combinatorial hits identified at the end of computational screening workflow applied in the present study.
Cmpd R1 Cmpd R1 Cmpd R1
HPCAR-1 HPCAR-33 HPCAR-89
HPCAR-2 HPCAR-35 HPCAR-90
HPCAR-6 HPCAR-37 HPCAR-91
HPCAR-7 HPCAR-41 HPCAR-92
HPCAR-8 HPCAR-44 HPCAR-108
HPCAR-14 HPCAR-45 HPCAR-111
HPCAR-15 HPCAR-46 HPCAR-114
HPCAR-22 HPCAR-52 HPCAR-123
HPCAR-23 HPCAR-54 HPCAR-126
HPCAR-25 HPCAR-55 HPCAR-130
(Continued)
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TABLE 2 | Continued
Cmpd R1 Cmpd R1 Cmpd R1
HPCAR-26 HPCAR-56 HPCAR-140
HPCAR-28 HPCAR-66 HPCAR-142
HPCAR-29 HPCAR-69 HPCAR-144
HPCAR-30
Three hit compounds (HPCAR-28, HPCAR-89 and HPCAR-142) were selected from this final set for synthesis and biological assessment.
terms in Table S3 revealed that all selected ligands showed high
values of van der Waals interaction energy (1GbindVdW values),
contributing to the ligand binding energy which emphasizes
critical importance of hydrophobic interactions in the stability of
the ligand–protein complexes.
Validation of Computational Screening
Workflow
In order to validate the developed computational protocol,
three compounds (HPCAR-28, HPCAR-89, and HPCAR-142
in Table 2) from final set of 40 hit candidates were selected
and synthesized. The selection was performed considering the
favorable computational scores, the bindingmodes, the structural
differences and synthetic accessibility. The best docked poses
along with the detailed interaction into the HIV-1 IN active site
of these representative compounds are depicted in Figure 4.
The compounds were able to establish a bis-bidentate
chelation of the Mg2+ ions, strong hydrophobic interactions (pi-
pi stackings) with the nucleotide DC16 and Pro145. Interestingly,
compounds HPCAR-28 and HPCAR-89 were able to form H-
bonds with DG4 that can further stabilize the binding mode
compared to HPCAR-142. Moreover, the fluorine atom of
HPCAR-28 can guarantee additional interactions within the
binding site with Pro145 and the sidechains of Glu152. This
slightly different pattern of interactions is also highlighted
by the differences in docking scores and 1Gbind values
(HPCAR-28 GlideScore −7.980 kcal/mol and 1Gbind −34.102
kcal/mol; HPCAR-89 GlideScore −6.648 kcal/mol and 1Gbind
−26.777 kcal/mol; HPCAR-142 −6.622 kcal/mol and 1Gbind
−25.759 kcal/mol; as reported in Tables S2, S3). Overall,
the in silico analysis showed that HPCAR-28 and HPCAR-
89 can better interact with the active site of HIV IN with
respect toHPCAR-142.
Regarding the investigation of the binding modes of our
derivatives, in our previous study (Sirous et al., 2019), we
discussed about the mutation of Tyr143 that confers resistance to
RLT. In particular, RLT established interactions with Tyr143 by
its oxadiazole moiety in both binary PFV-IN and modeled HIV-
1 IN complexes. Interestingly, our most promising derivatives
do not possess a moiety that can establish interactions with
this residue (i.e., oxadiazole in RLT). Furthermore, in this study
we investigated also two additional mutations that could confer
resistance to drugs including RLT and DTG, Gln148His and
Gly140Ser. The in silico analysis reported in Figure S1 showed the
superposition of the binding mode of RLT, DTG, and HPCAR-
28 into HIV-1 IN active site. Notably, the only binding mode
that can be strongly influenced by these residues (Tyr143, Gln148,
and Gly140) is the one of RLT. DTG can marginally interact with
the mentioned residues, whileHPCAR-28 is largely distant from
the residues that are responsible of the resistance (distance from
Me of HPCAR-28 to Tyr143 over 5 Å, to Gln148 over 9 Å, to
Gly140 over 10 Å; measured by the measurement tool available
in PyMOL). Remarkably, our HPCAR derivatives (HPCAR-28
and HPCAR-89) can additionally target the nucleotide DC16
and DG4 (Figure 4). This analysis is in perfect agreement with
the experimental data showing a dramatic decrease of affinity of
RLT for mutant HIV-1 IN and a lower decrease of affinity of
DTG. Consequently, it was assumed that the possible mutations
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FIGURE 4 | (Left) Binding modes of HPCAR-28 (purple sticks, A), HPCAR-89 (cyan sticks, B), and HPCAR-142 (yellow sticks, C) in the active site of the modeled
HIV-1 IN, as found by QPLD method. The solid ribbon model shows the backbone of the modeled HIV-IN, and the key amino acids of the binding site are shown as
lines. Two Mg2+ ions are displayed as violet spheres, while the viral DNA strands are depicted in orange. Hydrogen and metal coordination bonds are represented by
dashed lines. These figures were prepared using PyMOL. (Right) Ligand interaction diagrams for the selected compounds. These figures were prepared using Maestro.
of residues Tyr143, Gln148, and Gly140 could not influence the
binding of the HPCAR derivatives to IN.
Molecular Dynamics Simulation Studies
In order to better understand the behavior of the representative
compounds into HIV-IN enzyme for providing more reliable
results about the interactions of HPCAR-28, HPCAR-89, and
HPCAR-142 with HIV-IN, we performed MD simulations
starting from the docked poses reported in Figure 5 (see
Experimental Section for further details).
The three INIs reached an overall stability about after 20
ns. We observed that the pattern of interaction indicated by
the docking calculations are generally maintained during the
MD, confirming HPCAR-28 and HPCAR-89 as more potent
potential INIs with respect to the compound HPCAR-142.
Accordingly, the three compounds maintained the coordination
bond with the Mg2+ ions during the simulation as well as the
hydrophobic interactions with DC16 andDA17. We also observed
that HPCAR-28 and HPCAR-89 were able to establish and
maintain further contacts into the binding site with respect to
the compound HPCAR-142. In fact, the presence of a nitrogen
in the R1 group as in of HPCAR-28 and HPCAR-89 allowed
to the molecules to stabilize their binding mode by forming
further H-bonds with DNA during the simulations. Briefly,
the analysis of the computational studies allowed to propose
HPCAR-28 and HPCAR-89 as more potent INIs with respect to
the compoundHPCAR-142.
In summary, combining different computational techniques
for evaluating the affinity of the compounds for HIV IN binding
site we provided a more comprehensive in silico protocol
improving the probability to identify and select compounds
with relevant affinity for the selected binding site (Brogi et al.,
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FIGURE 5 | RMSD of the complexes HPCAR-28/HIV IN (A), HPCAR-89/HIV IN (B), HPCAR-142/HIV IN (C) (RMSD of the protein in a line formed by blue circles;
RMSD of the ligand in a line formed by red circles). RMSD were calculated between the final conformation and the starting conformation through the 100 ns of
the MD simulation.
2009). Accordingly, the presented screening workflow allowed to
select novel potential HIV-1 INIs based on HPCAR scaffold with
improved predicted pharmacological profile. Taking into account
also the synthetic feasibility three representative hit candidates
were then chosen for the synthesis and then biologically
evaluated for validating the applied computational approach.
Chemistry
In this study, 3-(benzyloxy)-6-methyl-4-oxo-4H-pyran-2-
carboxylic acid, BPCA was used as a key intermediate material
for the preparation of the three selected hit compounds.
Thus, this intermediate was first synthesized starting from
commercially available Kojic acid according to a synthetic
procedure previously employed in our laboratory (Sirous et al.,
2019). On the other hand, three different synthetic routes were
developed for the preparation of the amine fragments needed
for appending desired hydrophobic backbone to BPCA. The
methodologies adopted for the synthesis of amine compounds
AM-(1-3) are outlined in Figures 6–9, respectively.
As described in Figure 6, the synthesis of the amine fragment
AM-1 started using an efficient Suzuki–Miyaura cross-coupling
(SMC) (Tan et al., 2014) by reacting 2-bromopyridine 1 with
phenyl-boronic acid derivative 2 in the presence of tetrakis (tri-
phenylphosphine) palladium (0) as the catalyst, affording the
phenyl-pyridine derivative 3. Subsequently the nitrile group of
resulting compound 3was reduced to the corresponding primary
amine AM-1 by treatment with sodium borohydride and dry
nickel (II) chloride (Khurana and Gogia, 1997; Khurana and
Kukreja, 2002; Caddick et al., 2003).
A four-step synthetic procedure was employed for the
synthesis of the amine fragment AM-2 starting from 2-methyl-
imidazole 4 (Figure 7). The first step of the protocol consisted
of the double bromination of the imidazole ring which afforded
the dibromo-imidazole derivative 5 in a moderate yield. The
selective debromination of the vicinal dibromide 5 employing
sodium sulfite as the reducing agent in aqueous ethanol at
reflux temperature effectively provided product 6 (yield: 75%)
(Khurana and Gogia, 1997; Alonso-Alija et al., 2003). Bromo-
imidazole 6 underwent a classical SM coupling reaction with
phenyl-boronic acid 7, providing phenyl-imidazole derivative
8. Amine fragment AM-2 was finally obtained by reduction of
phenyl-imidazole derivative 8 using sodium borohydride and dry
nickel (II) chloride as described for AM-1 (Caddick et al., 2003).
The amine fragment AM-3 was prepared from commercially
available 3-aminobenzonitrile 9, following Figure 8. A
Clauson–Kaas reaction of 3-aminobenzonitrile 9 with
dimethoxytetrahydrofuran 10 catalyzed by hydrochloric
acid afforded the corresponding 1-phenylpyrrole derivative
11 in a good yield (82%) (Chatzopoulou et al., 2013).
The nitrile functionality of the resulting product was then
reduced in the presence of sodium borohydride and dry
nickel (II) chloride to furnish the desired amine compound
AM-3 (Caddick et al., 2003).
Finally, the representative hit compounds were prepared
by introduction of amine backbones to the benzyl-protected
pyranone BPCA under standard amide coupling conditions
(Sheehan et al., 1965; Sirous et al., 2019). The general
procedure employed for the synthesis of the final compounds
is summarized in Figure 9. The activation of carboxylic acid
group of BPCA as the corresponding derivative 12 using
EDCI and NHS as coupling reagents followed by treatment
with the desired amines led to 2-amido substituted pyranone
analogs BPCAR. The removal of the benzyl protecting group
of the obtained amide derivatives was then accomplished
by reaction with boron tribromide in dichloromethane at
room temperature to obtain three final target products,
HPCAR-28, HPCAR-89, and HPCAR-142, in 71–86% yield
(Kosak et al., 2015; Sirous et al., 2019).
Biological Activity Evaluation
For validating the computational protocol herein presented,
three representative compounds (HPCAR-28, HPCAR-89, and
HPCAR-142) were synthesized and biologically assessed for
HIV-1 IN catalytic inhibitory activity based on an in vitro
enzymatic assay. Given that most HIV-1 INIs such as RLT target
the ST step of the integration reaction, the inhibition of the ST
activity of HIV-1 IN was examined in these assays in addition to
overall HIV-1 IN inhibition. Moreover, assessment of the anti-
HIV-1 potential in MT-4 cells was performed in a multiple round
cell-based antiviral assay. Cytotoxicity of the selected compounds
for the target host cell was also evaluated and their therapeutic
indices were calculated. In these experiments, RLTwas employed
as a reference HIV-1 INI. The results for biological activities of
these hits were summarized in Table 3.
As reported in Table 3, biological evaluation confirmed the
favorable anti-HIV profile for the three newly synthesized
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FIGURE 6 | Procedure applied for the synthesis of the amine fragment AM-1. Reagents and conditions: (a) Pd(OAc)2, PPh3, K2CO3, dioxane/water, 24 h reflux; (b)
NaBH4, NiCl2 (dry), dry ethanol, 25
◦C.
FIGURE 7 | Procedure applied for the synthesis of the amine fragment AM-2. Reagents and conditions: (a) Br2, chloroform, 0–25
◦C; (b) Na2SO3, ethanol/water, 48 h
reflux; (c) Pd(OAc)2, PPh3, K2CO3, dioxane/water, 24 h reflux (d) NaBH4, NiCl2 (dry), dry ethanol, 25
◦C.
FIGURE 8 | Procedure applied for the synthesis of the amine fragment AM-3. Reagents and conditions: (a) 5N HCl, dioxane, 30min reflux; (b) NaBH4, NiCl2 (dry), dry
ethanol, 25◦C.
FIGURE 9 | General procedure applied for the final synthesis of three representative hit compounds based on HPCAR scaffold. Reagents and conditions: (a) NHS,
EDCI, Dichloromethane (dry), 25◦C, 3 h; (b) AR-CH2NH2 (amine compounds used for HPCAR-28, HPCAR-89, and HPCAR-142 are AM-1, AM-2, and AM-3,
respectively), 25◦C, 3 days; (c) BBr3, Dichloromethane (dry), 0–25
◦C.
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TABLE 3 | Results for anti-HIV activity, inhibitory potential of HIV-1 IN and cytotoxicity of the synthesized compounds and RLT.
Entry Overall HIV-1 IN activity
inhibition IC50 (µM)
a
HIV-1 IN strand transfer
activity inhibition IC50 (µM)
b
HIV-1 activity
inhibition EC50 (µM)
c
Cellular toxicity
CC50 (µM)
d
TIe
HPCAR-28 0.065 ± 0.01 3.37 ± 0.38 0.23 ± 0.18 >250 >1,087
HPCAR-89 0.27 ± 0.1 4.0 ± 0.34 2.34 ± 0.46 >125 >53.4
HPCAR-142 1.97 ± 1.06 17.49 ± 0.13 4.21 ± 0.52 >85.4 >20.3
HPb 0.37 ± 0.17 1.405 ± 0.01 1.72 ± 0.99 >250 >145
HPd 0.7 ± 0.31 1.54 ± 0.2 1.95 ± 0.93 195.5 ± 4.4 100.3
RLT 0.01 0.04 0.013 ± 0.008 >18.329 >1410
a,bConcentration required to inhibit 50% of the in vitro overall and strand transfer integrase activities, respectively.
cEffective concentration in which 50% inhibition is observed.
dCytotoxic concentration in which 50% of the cells are killed.
eTherapeutic index: defined by CC50/EC50 ratio.
entities, which demonstrated the ability to inhibit the catalytic
activities of HIV-1 IN in the low micromolar range and
highlighting the validity of the developed computational protocol
for optimizing the previous developed compound. The positive
influence of hydrophobic moiety modification of HPCAR
derivatives on the inhibitory activity was particularly evident
with phenyl-pyridine substituted derivative HPCAR-28. This
compound emerged as the most potent inhibitor among three
tested compounds with low nanomolar activity against HIV-1
IN (IC50 = 65 nM) as highlighted by the computational studies,
and a 6-fold improvement in anti-IN potency compared to
HPb (Figure 2 and Table 3; IC50 = 0.37µM) (Sirous et al.,
2019). Compounds HPCAR-89 and HPCAR-142 also showed
promising anti-IN activities in the low micromolar range. In
this regard, the incorporation of phenyl-imidazole moiety at
the carboxamide sidechain (compound HPCAR-89) proved to
be also advantageous since it led to a slight enhancement in
HIV-1 IN inhibitory activity (IC50 = 0.27µM) compared to
the respective para-fluorobenzyl amide analog. Although hit
compound HPCAR-142 bearing phenyl-pyrrole fragment was
less active than two other hits in HIV-1 IN inhibition (IC50
= 1.97µM), it is still a promising candidate compound for
further structural optimization. It was also found that synthesized
compounds have the capacity to inhibit the ST step of the HIV-
1 IN in the low micromolar range. These observations were
in agreement with the in silico analysis done, highlighting the
fundamental validity of the developed computational protocol
for optimizing the previous developed compound. Examination
of anti-HIV-1 activity of representative compounds based on cell-
based assay indicated that benzyl group replacement with desired
hydrophobic moieties was well tolerated for the inhibition of
HIV-1 replication as well. According to these results, antiviral
activities are reasonably correlated with HIV-1 IN inhibition
potencies thus confirming the mechanism of action of these anti-
HIV-1 agents. Accordingly, HPCAR-28 showed the best anti-IN
activity and it is the most active hit against HIV-1 infected cells
with an EC50 value of 0.23 µM.
The cytotoxicity assay also showed that the tested compounds
are safe and possess anti-HIV activity at non-cytotoxic
concentrations (CC50 values ranging from 85.4 to >250µM),
thus resulting in favorable therapeutic indices for the investigated
compounds. In particular, the most promising hit compound
(HPCAR-28) revealed an appreciable therapeutic index (TI >
1,087) comparable to that found for RLT (TI > 1,410). On the
contrary, the limited toxicity (>85.4µM) showed by HPCAR-
142 is potentially ascribable to the presence of the pyrrole moiety
that often presents some toxicity.
Overall, these results confirmed that three representative
hit compounds are able to achieve the desired level of
biological activities in terms of reduced toxicity and optimum
inhibitory activities against HIV-1 IN and HIV-1 in cell culture.
Furthermore, it was clearly verified that modification of the
hydrophobic aromatic moiety within the HPCAR derivatives can
lead to differences in HIV-1 IN inhibitory profiles. Moreover, this
research clearly confirms the key role of the in silico drug design
in medicinal chemistry to optimize compounds for a selected
binding site. Remarkably the presented protocol could be easily
translated to different targets in order to find suitable decoration
for optimizing promising hit compounds.
CONCLUSION
In the present study, we have reported the development of
a computational protocol for identifying novel analogs based
on recently disclosed 3-hydroxyl-pyran-4-one-2-carboxamides
(HPCAR) scaffold (Sirous et al., 2019) with improved activity
against HIV-1 IN. In particular, the in silico protocol allowed
us to replace the aromatic hydrophobic moiety of HPCAR with
appropriate hydrophobic aromatic/hetero-aromatic fragments.
To this end, we used a combinatorial side chain hopping
strategy. The resulting compounds (>37,000) were filtered
using different computational methodologies. Filtering criteria
included: appropriate calculated physico-chemical properties,
satisfactory docking score values, visual inspection, lower ligand
binding energies and proper behaviors into the HIV IN binding
site assessed by MD. By using these subsequent filtering tools, we
reduced the number of compounds from 1,803 to 40. Among
the 40 top hit compounds, three HPCAR derivatives were
chosen according to the relevant computational outputs coupled
to a synthetic accessibility. After the synthesis of HPCAR-28,
HPCAR-89, and HPCAR-142, the compounds underwent to
biological evaluation in order to validate the described in silico
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protocol. Gratifyingly, the results of pharmacological studies
showed that the representative hit compounds inhibited HIV-
1 IN in the low micromolar range. Among them, compound
HPCAR-28 showed the best inhibitory activity against HIV-1 IN
as well as the best inhibitory activity against HIV-1 replication
and HIV-1 IN strand transfer process along with a notable
therapeutic index and no appreciable cell toxicity.
These promising and encouraging results provide further solid
support for the potential exploitation of HPCAR scaffold in
the development of anti-retroviral drugs, paving the way to the
discovery of a new class of drugs against HIV-1 IN for treating
HIV infection.
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